Elevation Oncology slumps 25% on $50M public offering pricing Innovative oncology company, Elevation Oncology (ELEV) stock drops 25% as it proposes a public
KB Home CEO Jeffrey Mezger is certainly no housing newbie. He has seen just about everything in his 17 years